| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.76 | 64.8% | 73.6% |
| Total Income | 0.76 | 64.8% | 73.6% |
| Expenditure | 17.24 | 4.4% | 46.2% |
| PBT | -8.10 | 87.6% | 9.2% |
| Net Profit | -8.10 | 87.6% | 9.2% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.08 | 89.3% | 33.3% |
Opus Genetics Announces Q2 2026 Financial Results and Corporate Update
06 Aug 2026 · 6 Aug, 4:38 pm
Summary
Opus Genetics announced its financial results for the second quarter ended June 30, 2026, reporting license and collaborations revenue of $0.8 million, down from $2.9 million in the prior year period. The company's net loss widened to $8.1 million ($0.14 per diluted share) from $7.4 million ($0.12 per diluted share) in Q2 2025, primarily due to increased research and development expenses of $11.2 million. Despite the increased net loss, the company ended the quarter with $88.8 million in cash and cash equivalents, projecting a cash runway into 2029. Management highlighted significant progress in advancing its gene therapy pipeline, with key clinical data expected for OPGx-BEST1 in September 2026 and the OPGx-LCA5 trial initiating dosing in Q4 2026.
Key Highlights
- 1
Opus Genetics reported license and collaborations revenue of $0.8 million for the quarter ended June 30, 2026, a decrease from $2.9 million in the same period of 2025.
- 2
Research and development expenses increased to $11.2 million for Q2 2026 from $6.0 million in Q2 2025, driven by higher manufacturing and clinical costs.
- 3
General and administrative expenses were $6.0 million for Q2 2026, a slight increase from $5.8 million in Q2 2025.
- 4
The net loss for the quarter ended June 30, 2026, was $8.1 million, or ($0.14) per diluted share, compared to a net loss of $7.4 million, or ($0.12) per diluted share, in the prior year period.
- 5
As of June 30, 2026, Opus Genetics had $88.8 million in cash and cash equivalents, with an expected cash runway into 2029.
- 6
Enrollment was completed in Cohort 1 of the OPGx-BEST1 Phase 1/2 trial, with 3-month topline data expected in the second week of September 2026.
- 7
Enrollment was completed for the OPGx-LCA5 registrational Phase 3 trial, with dosing expected to begin in Q4 2026 and topline data by the end of 2027.
Management Comments
George Magrath
With a focus on execution, we are rapidly advancing five gene therapy programs that address significant unmet need in inherited retinal diseases, with OPGx-BEST1 Cohort 1 clinical data targeted for the second week of September and four additional clinical readouts expected in 2027. Based on recent FDA interactions, we finalized the OPGx-LCA5 registrational trial design. We have completed enrollment and expect to initiate participant dosing in the fourth quarter of this year. Our recent R&D Science Forum highlighted the significant progress we have made in advancing our pipeline. Our strong cash runway into 2029 positions us to initiate new clinical studies, deliver multiple data inflection points, pursue potential product approvals, and unlock opportunities for Priority Review Vouchers.
Informational and educational content only. Not investment advice.